Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor. As a result of concerns for potential infusion-related hypersensitivity reactions (HSRs), initial phase ...

Please provide your email address to receive an email when new articles are posted on . Researchers reported the survival benefit among patients with left-sided tumors and the overall study population ...

Adding Imfinzi and Avastin to transarterial chemoembolization led to a 23% reduction in the risk of progression or death in patients with liver cancer. Patients with unresectable hepatocellular ...

SILVER SPRING, Md., June 29 (Reuters) - She made her doctor repeat it several times: There's nothing there. There's nothing there. There's no evidence of cancer. Last May, after four years of battling ...

A progression-free survival benefit was observed in patients with advanced ovarian cancer including those with homologous recombination deficient-positive status who were treated with frontline chemo ...